Intravenous magnesium for pediatric sickle cell vaso-occlusive crisis: Methodological issues of a randomized controlled trial

Pediatric Blood and Cancer

Volumn 61, Issue 6, 2014, Pages 1049-1054

  Badaki Makun, Oluwakemi ^a   Scott, J Paul ^b   Panepinto, Julie A ^b   Casper, T Charles ^c   Hillery, Cheryl A ^b   Dean, J Michael ^c   Brousseau, David C ^b   Powell, Elizabeth ^d   Liem, Robert ^d   Alpern, Elizabeth ^e   Smith Whitley, Kim ^e   Chamberlain, James ^a   Hsu, Lewis ^a   Hogg, Neil ^b   Chumpitazi, Corrie ^f   Airewele, Gladstone ^f   Hickey, Robert ^g   Krishnamurti, Lakshmanan ^g   Leonard, Julie ^h   Hulbert, Monica ^h   Kannikeswaran, Nirupama ⁱ   Sarnaik, Sharada ⁱ   more..

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d Ann and Robert H Lurie Children's Hospital   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f TEXAS CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^h WASHINGTON UNIVERSITY   (United States)

ⁱ CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Enrollment; Hematology; Hemoglobinopathies; Pain medicine; Randomized controlled trial; Sickle cell anemia; Sickle cell disease; Vaso occlusive crisis

Indexed keywords

MAGNESIUM SULFATE; OPIATE; SODIUM CHLORIDE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; CUSTODY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; LENGTH OF STAY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PAIN; PARENTAL CONSENT; PEDIATRIC HOSPITAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL CRISIS; SICKLE CELL PAIN; VASO OCCLUSIVE CRISIS;

ENROLLMENT; HEMATOLOGY; HEMOGLOBINOPATHIES; PAIN MEDICINE; RANDOMIZED CONTROLLED TRIAL; SICKLE CELL ANEMIA; SICKLE CELL DISEASE; VASO-OCCLUSIVE CRISIS;

ANEMIA, SICKLE CELL; ANTI-INFLAMMATORY AGENTS; ARTERIAL OCCLUSIVE DISEASES; BIOLOGICAL MARKERS; COOPERATIVE BEHAVIOR; CYTOKINES; DOUBLE-BLIND METHOD; EMERGENCY SERVICE, HOSPITAL; HOSPITALS, PEDIATRIC; HOSPITALS, SPECIAL; HUMANS; HYPOTENSION; INFORMED CONSENT; INFUSIONS, INTRAVENOUS; INTERDISCIPLINARY COMMUNICATION; INTERPROFESSIONAL RELATIONS; LENGTH OF STAY; MAGNESIUM SULFATE; MULTICENTER STUDIES AS TOPIC; NARCOTICS; PAIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASODILATOR AGENTS;

EID: 84901698463     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24925     Document Type: Article

References (48)

1. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010; 376:2018-2031.
2. Ware RE, Schultz WH, Yovetich N, et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): A phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatr Blood Cancer 2011; 57:1011-1017.
3. Panepinto JA, O'Mahar KM, DeBaun MR, et al. Health-related quality of life in children with sickle cell disease: Child and parent perception. Br J Haematol 2005; 130:437-444.
4. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325:11-16.
5. Panepinto JA, Brousseau DC, Hillery CA, et al. Variation in hospitalizations and hospital length of stay in children with vaso-occlusive crises in sickle cell disease. Pediatr Blood Cancer 2005; 44:182-186.
6. Brousseau DC, Owens PL, Mosso AL, et al. Acute care utilization, rehospitalizations for sickle cell disease. JAMA 2010; 303:1288-1294.
7. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986; 314:1593-1599.
8. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339:5-11.
9. Hagar W, Vichinsky E. Advances in clinical research in sickle cell disease. Br J Haematol 2008; 141:346-356.
10. Mousa SA, Al Momen A, Al Sayegh F, et al. Management of painful vaso-occlusive crisis of sickle-cell anemia: Consensus opinion. Clin Appl Thromb Hemost 2010; 16:365-376.
11. Ellison AM, Shaw K. Management of vaso-occlusive pain events in sickle cell disease. Pediatr Emerg Care 2007; 23:832-838.
12. Field JJ, Knight-Perry JE, Debaun MR. Acute pain in children and adults with sickle cell disease: Management in the absence of evidence-based guidelines. Curr Opin Hematol 2009; 16:173-178.
13. Dunlop RJ, Bennett KC. Pain management for sickle cell disease. Cochrane Database Syst Rev 2006 Apr 19;(2):CD003350.
14. Benjamin LJ, Dampier CD, Jacox A, et al. Guideline for the management of acute and chronic pain in sickle-cell disease. American Pain Society. 1999.
15. Gladwin MT, Kato GJ, Weiner D, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: A randomized controlled trial. JAMA 2011; 305:893-902.
16. Styles L, Wager CG, Labotka RJ, et al. Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: Results of a feasibility study (PROACTIVE). Br J Haematol 2012; 157:627-636.
17. Peters-Lawrence MH, Bell MC, Hsu LL, et al. Clinical trial implementation and recruitment: Lessons learned from the early closure of a randomized clinical trial. Contemp Clin Trials 2012; 33:291-297.
18. Dampier CD, Smith WR, Wager CG, et al. IMPROVE trial: A randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: Rationale, design challenges, initial experience, and recommendations for future studies. Clin Trials 2013; 10:319-331.
19. Quinn CT, Stuart MJ, Kesler K, et al. Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. Br J Haematol 2011; 155:263-267.
20. Lebensburger JD, Sidonio RF, Debaun MR, et al. Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea. Pediatr Blood Cancer 2013; 60:1333-1337.
21. National Institutes of Health. Clinicaltrials.gov. http://www.clinicaltrials.gov/ct2/results?term=sickle+cell+&Search=Search. Accessed November 19, 2013.
22. Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A 2001; 98:15215-15220.
23. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350:886-895.
24. Nath KA, Katusic ZS, Gladwin MT. The perfusion paradox and vascular instability in sickle cell disease. Microcirculation 2004; 11:179-193.
25. Gladwin MT, Schechter AN, Ognibene FP, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 2003; 107:271-278.
26. Pritchard KA Jr, Ou J, Ou Z, et al. Hypoxia-induced acute lung injury in murine models of sickle cell disease. Am J Physiol Lung Cell Mol Physiol 2004; 286:L705-L714.
27. Yang Z-W, Gebrewold A, Nowakowski M, et al. Mg2+-induced endothelium-dependent relaxation of blood vessels and blood pressure lowering: Role of NO. Am J Physiol Regul Integr Comp Physiol 2000; 278:R628-R639.
28. Haenni A, Johansson K, Lind L, et al. Magnesium infusion improves endothelium-dependent vasodilation in the human forearm. Am J Hypertens 2002; 15:10-15.
29. Pearson PJ, Evora PR, Seccombe JF, et al. Hypomagnesemia inhibits nitric oxide release from coronary endothelium: Protective role of magnesium infusion after cardiac operations. Ann Thorac Surg 1998; 65:967-972.
30. Teragawa H, Matsuura H, Chayama K, et al. Mechanisms responsible for vasodilation upon magnesium infusion in vivo: Clinical evidence. Magnes Res 2002; 15:241-246.
31. Teragawa H, Kato M, Yamagata T, et al. Magnesium causes nitric oxide independent coronary artery vasodilation in humans. Heart 2001; 86:212-216.
32. Mathew R, Altura BM. Magnesium and the lungs. Magnesium 1988; 7:173-187.
33. Maier JA, Malpuech-Brugere C, Zimowska W, et al. Low magnesium promotes endothelial cell dysfunction: Implications for atherosclerosis, inflammation and thrombosis. Biochim Biophys Acta 2004; 1689:13-21.
34. Rochelson B, Dowling O, Schwartz N, et al. Magnesium sulfate suppresses inflammatory responses by human umbilical vein endothelial cells (HuVECs) through the NFkappaB pathway. J Reprod Immunol 2007; 73:101-107.
35. Weglicki WB, Phillips TM, Freedman AM, et al. Magnesium-deficiency elevates circulating levels of inflammatory cytokines and endothelin. Mol Cell Biochem 1992; 110:169-173.
36. Makis AC, Hatzimichael EC, Bourantas KL. The role of cytokines in sickle cell disease. Ann Hematol 2000; 79:407-413.
37. Brittain JE, Parise LV. Cytokines and plasma factors in sickle cell disease. Curr Opin Hematol 2007; 14:438-443.
38. Brousseau DC, Scott JP, Hillery CA, et al. The effect of magnesium on length of stay for pediatric sickle cell pain crisis. Acad Emerg Med 2004; 11:968-972.
39. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 1994; 330:733-737.
40. Orringer E, Casella J, Ataga K, et al. Purified Poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. JAMA 2001; 286:2099-2106.
41. Bernini JC, Rogers ZR, Sandler ES, et al. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998; 92:3082-3089.
42. Ruddock B. Chronic pain: Switching to an alternate opioid analgesic. CPJ/RPC 2005; 138:44-45.
43. Kuppermann N, Holmes JF, Dayan PS, et al. Identification of children at very low risk of clinically-important brain injuries after head trauma: A prospective cohort study. Lancet 2009; 374:1160-1170.
44. Chamberlain JM, Capparelli EV, Brown KM, et al. Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus. J Pediatr 2012; 160:667-672.
45. Holmes JF, Lillis K, Monroe D, et al. Identifying children at very low risk of clinically important blunt abdominal injuries. Ann Emerg Med 2013; 62:107-116.
46. De Lourdes Levy M, Larcher V, Kurz R, et al. Informed consent/assent in children. Statement of the Ethics Working Group of the Confederation of European Specialists in Paediatrics (CESP). Eur J Pediatr 2003; 162:629-633.
47. Wynn L, Miller S, Faughnan L, et al. Recruitment of infants with sickle cell anemia to a phase III trial: Data from the BABY HUG study. Contemp Clin Trials 2010; 31:558-563.
48. DeBaun MR, Sarnaik SA, Rodeghier MJ, et al. Associated risk factors for silent cerebral infarcts in sickle cell anemia: Low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood 2012; 119:3684-3690.